A Phase 3 interventional study of Cetuximab plus Platinum-based Doublet Chemotherapy and Cetuximab 500 mg/m^2 in Non-Small Cell Lung Cancer (NSCLC), sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-05.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 2 under way, none of them phase 3. Cetuximab · Carcinoma, Non-Small-Cell Lung.
Among the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2009, is one of 5 in phase 3, and was the 36th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →2 of the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18+
Jonathan Riess · Sites in United States
Ages 18+
By country, each count listing its studies:
Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 38 · Phase 3 6
First in 2000; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 583 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 63 across the 51 interventional studies. Of the 47 that completed or were terminated, 22 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 52 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
35 studies in Carcinoma, Non-Small-Cell Lung by Merck KGaA, Darmstadt, Germany: 1 open now, 4 under way, 1 of them phase 3. Of 30 finished, 24 (80%) have results posted.
Among the 35 studies in Carcinoma, Non-Small-Cell Lung by Merck KGaA, Darmstadt, Germany, this one is the 6th largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2009, is one of 9 in phase 3, and was the 9th registered.
Merck KGaA, Darmstadt, Germany’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck KGaA, Darmstadt, Germany’s 35 in Carcinoma, Non-Small-Cell Lung:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, randomized, multinational, non-comparative, phase IIIb trial with 2 parallel groups will screen about 1400 subjects with stage IIIB non-small cell lung cancer (NSCLC) with pleural effusion or stage IV NSCLC. It is expected that of approximately 1200 (85 percent) subjects who will be included, about 1000 will be Caucasian; about 120 Asian, and the remainder (about 80) will be of other ethnic origin (that is neither Caucasian nor Asian). Approximately 480 (40 percent) subjects are expected to be free of progression at the end of combination treatment with cetuximab and platinum-based chemotherapy. These subjects will be eligible for randomization to intravenous cetuximab maintenance therapy with either 500 milligram per square meter (mg/m\^2) every 2 weeks or 250 mg/m\^2 weekly (q1w); about 240 subjects are expected per group.
The trial will be performed in a community practice setting, with approximately 230 centers participating in the trial worldwide (planned countries are Argentina, Australia, Austria, Belgium, Brazil, Chile, China, Colombia, Czech Republic, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Mexico, Netherlands, Poland, Portugal, Russia, Singapore, Slovakia, South Africa, South Korea, Spain, Switzerland, Taiwan, Turkey, United Kingdom and Venezuela). With noncompetitive enrollment, approximately 4 to 8 subjects are expected to be enrolled at each center. Enrollment in the individual centers is generally limited to a maximum of 8 subjects. If any of these subjects does not receive trial treatment for any reason or discontinue all trial treatment at the first visit, additional subjects may be enrolled until 8 subjects were treated. The primary endpoint of the trial will be overall survival time from inclusion into the trial to death. Additional secondary efficacy endpoints will be time to treatment failure, tumor response, and disease control rate. Other endpoints will include safety and toxicity, compliance with maintenance therapy, subject satisfaction and translational research (TR) (for subjects with tumor samples available).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Cetuximab plus Platinum-based Doublet Chemotherapy
Drug: Cetuximab 500 mg/m^2
Drug: Cetuximab 250 mg/m^2
Single first dose of cetuximab 400 mg/m\^2 infusion will be administered intravenously over 120 minutes (min) followed by cetuximab 250 mg/m\^2 intravenous infusion over 60 min q1w with background platinum-based doublet chemotherapy up to maximum of 6 cycles, until progressive disease, unacceptable toxicity, or withdrawal of consent. Platinum based doublet chemotherapy will be administered as intravenous infusion as per study center included: vinorelbine 25 mg/m\^2 on Day 1 (D1) and Day 8 (D8)+cisplatin 80 mg/m\^2 on D1; or gemcitabine 1250 mg/m\^2 on D1 and D8+cisplatin 75 mg/m\^2 on D1; or gemcitabine 1000 mg/m\^2 on D1 and D8+carboplatin at dose to reach area under curve (AUC)5 milligram\*hour/milliliter (mg\*hr/mL) on D1; or Docetaxel 75 mg/m\^2 on D1+cisplatin 75 mg/m\^2 on D1; or paclitaxel 175 mg/m\^2 on D1+cisplatin 80 mg/m\^2 on D1; or paclitaxel 200 mg/m\^2 on D1+carboplatin at dose to reach AUC6 mg\*hr/mL on D1, of each 3-week treatment cycle for a maximum of 6 cycles.
Drug page: Cetuximab
Subjects who will be free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 500 mg/m\^2 as intravenous infusion every 2 weeks, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent.
Also known as: Erbitux
Drug page: Cetuximab
Subjects who will free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 250 mg/m\^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.
Also known as: Erbitux
Overall Survival (OS) Time
The OS time is defined as the time from trial inclusion to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier.
Time frame: Time from trial inclusion to death or last day known to be alive, reported between day of first participant included, that is, Jan 2009 until cut-off date (17 Dec 2011)
Percentage of Participants With 1-year Overall Survival
The OS time is defined as the time from trial inclusion to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier. Percentage of participants who were still alive until one year after the last participant was included (March 2010).
Time frame: Time from trial inclusion to death or last day known to be alive, reported between day of first participant included, that is, Jan 2009 until one year after the last participant was included (March 2010)
Overall Survival (OS) Time (From Randomization to Cetuximab Maintenance Regimen Until Death)
The OS time is defined as the time from randomization in cetuximab maintenance regimen to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier.
Time frame: Time from randomization in cetuximab maintenance regimen to death or last day known to be alive, reported between day of first participant randomized, that is, May 2009 until cut-off date (17 Dec 2011)
Time to Treatment Failure
Time to treatment failure is defined as the time from trial inclusion to date of either first occurrence of progression, discontinuation of treatment due to progression or adverse event, withdrawal of consent or lost to follow up, start of further anticancer therapy, or death, whichever is earlier. Participants without events are censored either at the time of their last drug intake, or on the day of inclusion (Day 1) if they received no study drug.
Time frame: Time from trial inclusion to treatment failure or last drug intake, reported between day of first participant included, that is, Jan 2009 until cut-off date (17 Dec 2011)
Time to Treatment Failure (From Randomization to Cetuximab Maintenance Regimen Until Death)
Time from randomization in cetuximab maintenance regimen to date of either first occurrence of progression, discontinuation of treatment due to progression or adverse event, withdrawal of consent or lost to follow up, start of further anticancer therapy, or death, whichever is earlier. Participants without events are censored either at the time of their last drug intake, or on the day of randomization (Day 1 of maintenance therapy) if they received no study drug.
Time frame: Time from randomization in cetuximab maintenance regimen to treatment failure or last drug intake, reported between day of first participant randomized, that is, May 2009 until cut-off date (17 Dec 2011)
Percentage of Participants With Best Unconfirmed Tumor Response in the Combination Therapy Phase
The response rate is defined as the percentage of participants having achieved complete response (CR) or partial response (PR) as the unconfirmed best overall response (BOR) according to centrally reviewed investigator assessments based on an independent review charter (IRC). As per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: CR = Disappearance of all target lesions; PR = at least 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Time frame: Evaluations were performed every 2 cycles during combination therapy period until progression and at the end of combination therapy period, reported between day of first participant included, that is, Jan 2009, until cut-off date, (17 Dec 2011)
Percentage of Participant With Best Unconfirmed Tumor Response for the Whole Study Period
The response rate is defined as the percentage of participants having achieved CR and PR as the BOR according to IRC assessment in combination therapy phase and radiological assessments (based on response evaluation criteria in solid tumors \[RECIST\] Version 1.0) in the maintenance therapy phase. As per RECIST v1.0 for target lesions and assessed by MRI: CR = Disappearance of all target lesions; PR = at least 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Time frame: Evaluations were performed every 2 cycles during combination therapy and 6-weekly during maintenance therapy period until progression and at end of both periods, reported between day of first participant included, Jan 2009 until cut-off date (17 Dec 2011)
Percentage of Participants With Disease Control in the Combination Therapy Phase
The disease control rate is defined as the percentage of participants having achieved complete response or partial response or stable disease as the unconfirmed BOR according to IRC assessment.
Time frame: Evaluations were performed every 2 cycles during combination therapy period until progression and at the end of combination therapy period, reported between day of first participant included, that is, Jan 2009, until cut-off date, (17 Dec 2011)
Percentage of Participants With Disease Control for the Whole Study Period
The disease control rate is defined as the percentage of participants having achieved complete response or partial response or stable disease as the unconfirmed best overall response according to IRC assessment in combination therapy phase and radiological assessments (based on RECIST Version 1.0 criteria) in the maintenance therapy phase.
Time frame: Evaluations were performed every 2 cycles during combination therapy and 6-weekly during maintenance therapy period until progression and at end of both periods, reported between day of first participant included, Jan 2009 until cut-off date (17 Dec 2011)
First/last participants (informed consent): January 2009/17 March 2010. Clinical data cut-off: 17 December 2011
| Milestone | Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy | Cetuximab 500 mg/m^2 Every 2 Weeks | Cetuximab 250 mg/m^2 Weekly |
|---|---|---|---|
| Started | 583 | 0 | 0 |
| Completed | 313 | 0 | 0 |
| Not completed | 270 | 0 | 0 |
| Withdrew: Adverse event | 77 | 0 | 0 |
| Withdrew: Death | 28 | 0 | 0 |
| Withdrew: Protocol violation | 4 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 21 | 0 | 0 |
| Withdrew: Progressive disease | 114 | 0 | 0 |
| Withdrew: Sympt. deterioration w/o pd by imaging | 14 | 0 | 0 |
| Withdrew: Other | 11 | 0 | 0 |
| Milestone | Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy | Cetuximab 500 mg/m^2 Every 2 Weeks | Cetuximab 250 mg/m^2 Weekly |
|---|---|---|---|
| Started | 0 | 157 | 154 |
| Completed | 0 | 112 | 109 |
| Not completed | 0 | 45 | 45 |
| Withdrew: Investigational study phase ongoing | 0 | 45 | 45 |
The OS time is defined as the time from trial inclusion to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier.
| months | Cetuximab 500 mg/m^2 Every 2 Weeks | Cetuximab 250 mg/m^2 Weekly |
|---|---|---|
| Overall Survival (OS) Time | 16.1 (13.6 to 18.2) | 15.5 (13.2 to 19.7) |
The OS time is defined as the time from randomization in cetuximab maintenance regimen to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier.
| months | Cetuximab 500 mg/m^2 Every 2 Weeks | Cetuximab 250 mg/m^2 Weekly |
|---|---|---|
| Overall Survival (OS) Time (From Randomization to Cetuximab Maintenance Regimen Until Death) | 12.6 (10.1 to 14.8) | 12.6 (9.3 to 16.0) |
Time to treatment failure is defined as the time from trial inclusion to date of either first occurrence of progression, discontinuation of treatment due to progression or adverse event, withdrawal of consent or lost to follow up, start of further anticancer therapy, or death, whichever is earlier. Participants without events are censored either at the time of their last drug intake, or on the day of inclusion (Day 1) if they received no study drug.
| months | Cetuximab 500 mg/m^2 Every 2 Weeks | Cetuximab 250 mg/m^2 Weekly |
|---|---|---|
| Time to Treatment Failure | 5.8 (5.6 to 6.6) | 6.6 (6.1 to 6.9) |
Time from randomization in cetuximab maintenance regimen to date of either first occurrence of progression, discontinuation of treatment due to progression or adverse event, withdrawal of consent or lost to follow up, start of further anticancer therapy, or death, whichever is earlier. Participants without events are censored either at the time of their last drug intake, or on the day of randomization (Day 1 of maintenance therapy) if they received no study drug.
| months | Cetuximab 500 mg/m^2 Every 2 Weeks | Cetuximab 250 mg/m^2 Weekly |
|---|---|---|
| Time to Treatment Failure (From Randomization to Cetuximab Maintenance Regimen Until Death) | 2.6 (2.1 to 2.8) | 2.8 (2.6 to 4.0) |
The response rate is defined as the percentage of participants having achieved complete response (CR) or partial response (PR) as the unconfirmed best overall response (BOR) according to centrally reviewed investigator assessments based on an independent review charter (IRC). As per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: CR = Disappearance of all target lesions; PR = at least 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
| percentage of participants | Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy |
|---|---|
| Percentage of Participants With Best Unconfirmed Tumor Response in the Combination Therapy Phase | 36.2 (32.3 to 40.2) |
The response rate is defined as the percentage of participants having achieved CR and PR as the BOR according to IRC assessment in combination therapy phase and radiological assessments (based on response evaluation criteria in solid tumors \[RECIST\] Version 1.0) in the maintenance therapy phase. As per RECIST v1.0 for target lesions and assessed by MRI: CR = Disappearance of all target lesions; PR = at least 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
| percentage of participants | Cetuximab 500 mg/m^2 Every 2 Weeks | Cetuximab 250 mg/m^2 Weekly |
|---|---|---|
| Percentage of Participant With Best Unconfirmed Tumor Response for the Whole Study Period | 54.8 (46.6 to 62.7) | 57.8 (49.6 to 65.7) |
The disease control rate is defined as the percentage of participants having achieved complete response or partial response or stable disease as the unconfirmed BOR according to IRC assessment.
| percentage of participants | Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy |
|---|---|
| Percentage of Participants With Disease Control in the Combination Therapy Phase | 65.7 (61.7 to 69.5) |
The disease control rate is defined as the percentage of participants having achieved complete response or partial response or stable disease as the unconfirmed best overall response according to IRC assessment in combination therapy phase and radiological assessments (based on RECIST Version 1.0 criteria) in the maintenance therapy phase.
| percentage of participants | Cetuximab 500 mg/m^2 Every 2 Weeks | Cetuximab 250 mg/m^2 Weekly |
|---|---|---|
| Percentage of Participants With Disease Control for the Whole Study Period | 98.7 (95.5 to 99.8) | 99.4 (96.4 to 100) |
The OS time is defined as the time from trial inclusion to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier. Percentage of participants who were still alive until one year after the last participant was included (March 2010).
| percentage of participants | Cetuximab 500 mg/m^2 Every 2 Weeks | Cetuximab 250 mg/m^2 Weekly |
|---|---|---|
| Percentage of Participants With 1-year Overall Survival | 62.8 (54.7 to 70.0) | 64.4 (56.2 to 71.4) |
Collected over Time from Baseline up to 30 days after the last dose of study treatment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy | — | 243/583 (41.7%) | 564/583 (96.7%) |
| Cetuximab 500 mg/m^2 Every 2 Weeks | — | 30/156 (19.2%) | 121/156 (77.6%) |
| Cetuximab 250 mg/m^2 Weekly | — | 33/155 (21.3%) | 136/155 (87.7%) |
| Event | Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy | Cetuximab 500 mg/m^2 Every 2 Weeks | Cetuximab 250 mg/m^2 Weekly |
|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 32/583 | 1/156 | 0/155 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 20/583 | 0/156 | 0/155 |
| PneumoniaInfections and infestations | 17/583 | 4/156 | 4/155 |
| ThrombocytopeniaBlood and lymphatic system disorders | 13/583 | 0/156 | 0/155 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 12/583 | 0/156 | 1/155 |
| VomitingGastrointestinal disorders | 11/583 | 0/156 | 1/155 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 10/583 | 2/156 | 2/155 |
| DiarrhoeaGastrointestinal disorders | 9/583 | 0/156 | 0/155 |
| PyrexiaGeneral disorders | 9/583 | 0/156 | 1/155 |
| LeukopeniaBlood and lymphatic system disorders | 8/583 | 0/156 | 0/155 |
| Event | Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy | Cetuximab 500 mg/m^2 Every 2 Weeks | Cetuximab 250 mg/m^2 Weekly |
|---|---|---|---|
| RashSkin and subcutaneous tissue disorders | 306/583 | 40/156 | 40/155 |
| NauseaGastrointestinal disorders | 212/583 | 3/156 | 9/155 |
| NeutropeniaBlood and lymphatic system disorders | 208/583 | 0/156 | 0/155 |
| AnaemiaBlood and lymphatic system disorders | 134/583 | 9/156 | 15/155 |
| AstheniaGeneral disorders | 124/583 | 6/156 | 16/155 |
| VomitingGastrointestinal disorders | 122/583 | 2/156 | 8/155 |
| DiarrhoeaGastrointestinal disorders | 120/583 | 6/156 | 15/155 |
| FatigueGeneral disorders | 114/583 | 7/156 | 13/155 |
| ThrombocytopeniaBlood and lymphatic system disorders | 112/583 | 0/156 | 0/155 |
| Decreased appetiteMetabolism and nutrition disorders | 112/583 | 8/156 | 13/155 |
| Age, Continuous(years) | Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy |
|---|---|
| Mean | 60.4 ± 9.28 |
| Sex: Female, Male(Participants) | Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy |
|---|---|
| Female | 147 |
| Male | 436 |
The record gives a start of Jan 2009, a primary completion of Dec 2011 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cetuximab
Carcinoma, Non-Small-Cell Lung →
Merck KGaA, Darmstadt, Germany →